Tag
In the phase 3 CARES-009 trial, perioperative camrelizumab combined with rivoceranib significantly improved event-free survival and major pathological response in patients with resectable high-risk hepatocellular carcinoma, compared to surg
A French nationwide cohort study reveals no significant differences in effectiveness or safety between atezolizumab and durvalumab as first-line PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer.
Immune-checkpoint inhibitors combined with chemotherapy have redefined treatment for advanced biliary tract cancer, offering improved survival despite challenges posed by tumor heterogeneity and biomarker limitations. Ongoing research explo
The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.
Neoadjuvant nivolumab combined with ipilimumab shows promising long-term survival and safety in potentially resectable hepatocellular carcinoma, with immunotherapy-induced tertiary lymphoid structures correlating with response.
Non-proportional hazards in hepatocellular carcinoma immunotherapy trials can distort interim and final survival outcomes. Employing tailored statistical strategies ensures robust, clinically meaningful analyses and informed decision-making
This article reviews a pivotal phase 3 trial demonstrating telitacicept’s efficacy and safety in active SLE, highlighting its potential as a novel targeted therapy.
The 9-year follow-up of the CheckMate 238 trial confirms that nivolumab offers longer recurrence-free survival than ipilimumab in resected stage III/IV melanoma, with durable safety and favorable distant metastasis-free survival.
Atezolizumab maintenance therapy after multimodal definitive treatment failed to improve event-free or overall survival in high-risk LA SCCHN patients in the phase 3 IMvoke010 trial, highlighting challenges in immunotherapy for this setting
This study demonstrates that disitamab vedotin plus toripalimab significantly improves survival outcomes over chemotherapy in untreated HER2-positive advanced urothelial cancer.
This review discusses a phase 3 trial demonstrating that sacituzumab govitecan improves progression-free survival in untreated, advanced triple-negative breast cancer patients not eligible for PD-1/PD-L1 inhibitors.
Over the past two decades, advances in therapy have doubled the median survival of multiple myeloma patients, transforming this once devastating cancer into a more manageable disease through targeted drugs and immune therapies.
Marengo Therapeutics reports promising Phase 2 results for invikafusp alfa, showing significant tumor shrinkage and disease control in advanced solid tumors with high mutation burden or MSI-H/dMMR.
This study identifies specific cancer-testis antigens (CTAs) as promising targets for personalized immunotherapy in head and neck squamous cell carcinoma (HNSCC), validated across multiomic datasets to enhance therapeutic precision.
This study assesses seizure remission and epilepsy risk in 236 anti-LGI1 encephalitis patients, highlighting immunotherapy’s role in seizure control and identifying biomarkers linked to persistent cognitive impairment and long-term ou
This retrospective multicenter study found that early intravenous immunoglobulin treatment in anti-IgLON5 disease is linked to reduced disability and mortality, highlighting a promising immunotherapeutic strategy for this rare autoimmune en
This article reviews the phase 3 POD1UM-304 trial demonstrating that adding retifanlimab to platinum-based chemotherapy improves overall survival in first-line metastatic NSCLC, highlighting its potential as a new standard of care.
This phase 3 trial compares benmelstobart plus anlotinib to sunitinib, demonstrating improved progression-free survival and manageable safety in untreated advanced renal cell carcinoma.
Interim results from the phase 2 SunRISe-4 trial demonstrate that neoadjuvant TAR-200 combined with cetrelimab significantly improves pathological complete response rates versus cetrelimab alone in muscle-invasive bladder cancer patients in
Reprogramming glutamine metabolism via Asct2 transporter expression improves BCMA-CAR T cell fitness, proliferation, and anti-myeloma efficacy under glutamine-limited conditions, offering a promising strategy to overcome metabolic immune ev
